Skip to content

Pharmacycle

Active Private limited companyfounded 2018active for 8 yearsWillebroekkaai 25, 1000 BrusselsKBO/BCE: BE 0696.815.336

Annual accounts 2025

micro format, filed on 29-05-2026, 63 days before the deadline
€10,640
▼ 81.0%
€7,199
▼ 86.2%
€5,640
▼ 85.5%
€22,704
▲ 10.3%
70.8%
▲ 38.9 percentage points
2.89
▲ 1.55

Turnover is estimated at about €110,000, probably between €40,000 and €240,000. The micro format does not state turnover.

Balance sheet

balance sheet total €41,191 on 31-12-2025
What the company ownsHow it is paid for

in euro

in euro

Position in the sector

70.8%

Higher than 81% of the 25,459 companies filing micro accounts in retail trade (NACE 47) in 2025.

2.89

Higher than 76% of the 24,457 companies filing micro accounts in retail trade (NACE 47) in 2025.

13.7%

Higher than 77% of the 24,646 companies filing micro accounts in retail trade (NACE 47) in 2025.

Pharmacycle Middle half of the sector 80% of the sector Micro accounts in retail trade (NACE 47)

Net result: middle half · Equity: middle half · Balance sheet total: bottom quarter · Working capital: middle half

Key figures and ratios

per financial year, computed from the annual accounts
Line Trend202520242023202220212020201920187 months
10,24055,47827,01814,6586,01812,08819,00116,482
8,68141,98420,16810,8414,94010,29814,14112,058
03,2255,03904,2157,4143,0194,147
-9,283-18,4635,8445,4153-7,151-2,210-
22,70420,59133,58326,56717,94316,48229,82119,511
70.8%31.9%64.5%88.9%77.4%74.8%83.8%63.6%
2.891.342.697.433.812.885.502.49
0.412.130.550.120.290.340.190.57
19.3%133.0%41.5%22.9%7.1%30.7%35.7%49.2%
13.7%42.5%26.8%20.4%5.5%22.9%29.9%31.3%
35.37over 10078.8688.2922.46---

A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.

Filed annual accounts

as filed with the National Bank, click a year to choose it
Line Trend202520242023202220212020201920187 months
Balance sheet: assets
20/58 41,19191,39262,90938,43535,07434,79840,88935,916
21/28 6,4739,5149,4697,73910,7489,5394,4483,341
22/27 6,4739,5149,4697,73910,7489,5394,4483,341
23 1,6061,785------
24 4,8687,7309,4697,73910,7489,5394,4483,341
29/58 34,71881,87853,44030,69624,32525,25936,44132,575
29 -----2,901--
291 -----2,901--
40/41 18,28818,05622,2525,8355,0073,0429,9843,972
40 10,5328,73011,1041,4112,639-7,5463,972
41 7,7569,32611,1484,4242,3673,0422,437-
50/53 13,07751,233------
54/58 2,73112,01430,47624,63219,21719,21526,36528,576
490/1 6225767122291011019227
Balance sheet: equity and liabilities
10/49 41,19191,39262,90938,43535,07434,79840,88935,916
10/15 29,17829,17840,59434,18727,15626,02134,26922,852
10/11 2,0002,0002,0002,0002,0002,00012,40012,400
100 ------18,60012,400
101 ------6,200-
13 27,17827,17838,59432,18725,15624,02121,86910,452
130 ------1,2401,240
133 27,17827,17838,59432,18725,15624,02120,6299,212
17/49 12,01362,21422,3154,2477,9188,7776,62013,063
17 -9282,4581191,535---
170/4 -9282,4581191,535---
42/48 12,01361,28719,8574,1296,3838,7776,62013,063
42 9281,5301,5751,4161,404---
44 3037621,8659102,9912,4963,0985,284
440/4 3037621,8659102,9912,4963,0985,284
46 --117-----
45 5,1438,7745,8481,0031,1884572,7106,611
450/3 5,1438,7745,8481,0031,188457374,420
454/9 ------2,6732,191
47/48 5,64050,22010,4528008005,8238121,168
Income statement
76A --97-----
9900 10,64055,86527,40215,0066,36612,43619,34816,829
630 3,0413,1803,3093,0093,0062,3231,913806
640/8 400387384348348348348348
9901 7,19952,29823,70911,6493,0139,76617,08815,676
75/76B 5408174341389325853-
75 5408174341389325853-
65/66B 290206343166268545271
65 290206343166268545271
9903 7,45052,90923,80011,6202,8379,97017,08915,604
67/77 1,81014,1056,9413,7899031,9944,8604,352
9904 5,64038,80416,8597,8311,9357,97612,22811,252
9905 5,64038,80416,8597,8311,9357,97612,22811,252
Appropriation of the result
9906 5,64038,80416,8597,8311,9357,97612,22811,252
791/2 -11,41610,452-----
691/2 --16,8597,0311,1352,15211,41610,452
6920 -------1,240
6921 --16,8597,0311,1352,15211,4169,212
694/7 5,64050,22010,4528008005,823812800
694 5,64050,22010,4528008005,823812800
Document PDFPDFPDFPDFPDFPDFPDFPDF

The full notes are in the filed accounts (PDF).

Source: Annual accounts 2025 (PDF), filed on 29-05-2026.

Filings

each dot is a set of accounts, on the day it reached the National Bank
Financial year Type Filed Reference Document
31-12-2025 micro format 29-05-2026 2026-00125468 PDF
31-12-2024 micro format 21-02-2025 2025-00037296 PDF
31-12-2023 micro format 04-06-2024 2024-00110491 PDF
31-12-2022 micro format 30-05-2023 2023-00098335 PDF
31-12-2021 micro format 13-06-2022 2022-20058395 PDF
31-12-2020 micro format 03-06-2021 2021-16800137 PDF
31-12-2019 micro format 22-07-2020 2020-32400353 PDF
31-12-2018 micro format 01-07-2019 2019-25200073 PDF

Investments

fixed assets acquired
Item20252024202320222021
Tangible fixed assets-€3,225€5,039-€4,215
€3,041€3,180€3,309€3,009€3,006

Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)

Insights on Pharmacycle

The operating result for 2025 is 86% lower than in 2024 and the lowest since 2021.

Debt's share of the balance-sheet total falls from 68.1% to 29.2%. Debt is lower.

Next steps